CARTIMMUNE: A Single-Center Study of Patients with Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV-101)

The purpose of the proposed study is to assess the safety, tolerability, and efficacy of KYV-101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases, including IIM, dcSSc, SLE, and AAV.

We will use your personal health information, information from the tests and procedures done for the study, and information about how the study treatment affects you to help determine if the study treatment is safe and effective in treating dcSSc. 

There are many factors that determine if you are eligible.  Some requirements include: 

• Diagnosed with dcSSc within the last 5 years 

• Skin involvement near the elbow and/or knee 

All subjects who complete the study or discontinue from the study after receiving KYV-101 will be asked to participate in a separate long term follow up study for continues monitoring for life or as mandated by local regulatory requirements.

You are expected to attend all study visits and stay in the hospital during your infusion. During some or all of the visits, you will have physical exams, lung function tests, ECG’s (electrocardiogram), echocardiograms, blood and urine collections and complete questionnaires and a temperature diary.

Thank you for your interest! If you wish to learn more and sign up for the study, please contact:

LAUREN BAKER

rheumatologyresearch@uphs.upenn.edu
215-614-4417